Evernow BBB and Consumer Complaint Trends: An Independent Review

What Is Evernow and How Does It Work?

Evernow is a subscription-based telehealth company that focuses exclusively on perimenopause and menopause. The model is straightforward: you pay a membership fee, complete an intake questionnaire, consult asynchronously or synchronously with a clinician, and receive a prescription for menopausal hormone therapy (MHT) or non-hormonal alternatives shipped to your door or sent to a local pharmacy.

The company targets a real unmet need. Only about 22 percent of U.S. Ob-gyns feel adequately trained to manage menopause, and the average woman waits years before her symptoms are addressed. Telehealth platforms like Evernow exist partly because that gap is so wide.

What Evernow Offers Clinically

Evernow's clinical menu centers on menopausal hormone therapy, the most effective treatment for vasomotor symptoms (hot flashes, night sweats) according to The Menopause Society 2022 Position Statement. Prescribers on the platform can write for:

• Systemic estrogen (patches, gels, sprays, oral tablets)
• Micronized progesterone (for women with a uterus)
• Vaginal estrogen for genitourinary syndrome of menopause (GSM)
• Non-hormonal options including SSRIs, SNRIs, and gabapentin

The platform does not, at this time, offer fertility treatment, postpartum care, or PCOS-specific management pathways. Women in the perimenopause transition (typically beginning in the mid-40s) are the primary audience, though postmenopausal women also use the service.

The Cash-Pay Model: What You Are Actually Paying For

Evernow charges a membership fee (approximately $145 per year as of early 2025, though pricing has changed multiple times) separate from medication costs. Medications are not always covered by insurance when obtained through the platform. This distinction matters because many complaint patterns trace back to unclear communication about total cost.

Evernow's BBB Profile: What the Ratings Actually Show

Evernow is not accredited by the Better Business Bureau as of early 2025. The BBB assigns ratings based on complaint history, transparency, and responsiveness, not on clinical quality. An absence of accreditation does not mean a company is unsafe, but it does mean BBB has not verified that the business meets its standards.

When evaluating any telehealth platform's BBB profile, three data points matter more than the letter grade alone:

1. Volume of complaints relative to company size. A handful of complaints from a company serving tens of thousands of women is a different signal than a handful from a company with a few hundred customers.
2. Complaint category. Billing and service complaints tell a different story than safety or prescription error complaints.
3. Resolution rate. Does the company respond and resolve, or ignore?

Evernow's BBB complaint record, along with Trustpilot and Reddit-sourced reports reviewed for this article, shows a pattern centered on billing disputes, subscription auto-renewal confusion, difficulty canceling, and delayed or unanswered clinician messages. Safety-specific complaints (wrong drug, wrong dose, dangerous prescribing) appear far less frequently than administrative ones.

The Most Common Complaint Categories

Billing and subscription issues represent the largest cluster. Women report being charged after cancellation requests, confusion about what the membership fee covers versus medication costs, and difficulty reaching billing support. This mirrors complaints seen across the direct-to-consumer telehealth sector broadly, not a pattern unique to Evernow.

Communication delays are the second most cited issue. Asynchronous telehealth depends on timely clinician response. Women in perimenopause managing active symptoms report frustration when follow-up messages go days without a reply.

Prescription access problems form a third cluster. These include delays in prescription transmission to pharmacies, formulary mismatches where a prescribed drug is not available through the platform's pharmacy partner, and difficulty obtaining refills.

Positive reviews, which exist in meaningful numbers on Trustpilot and in Reddit menopause communities, credit Evernow with being one of the few affordable options that takes perimenopause symptoms seriously and prescribes FDA-approved MHT without the dismissiveness some women report from in-person providers.

Is Evernow Legit? A Structured Clinical Assessment

Yes, Evernow is a real, operating telehealth company with licensed prescribers and real FDA-approved medications. "Legit" in the colloquial sense means: it is not a scam, it does not sell counterfeit drugs, and it connects you with actual clinicians. On those points, the evidence is clear.

The harder question is whether it delivers adequate clinical care for your specific situation. That answer depends on your life stage, your symptom complexity, and your tolerance for an asynchronous model.

How Evernow Compares Against Clinical Standards

ACOG Practice Bulletin 141 on menopausal hormone therapy and The Menopause Society's 2022 Position Statement both emphasize individualized risk assessment before initiating MHT. That assessment should include:

• Cardiovascular risk (history of VTE, stroke, coronary artery disease)
• Breast cancer history or family history with BRCA consideration
• Uterine status (intact uterus requires progestogen to protect endometrium)
• Bone density history if relevant
• Contraindications including active liver disease and unexplained vaginal bleeding

A well-designed telehealth intake can capture all of this. The question is whether Evernow's intake is thorough enough and whether clinicians flag contraindications consistently. Complaints reviewed for this article did not surface a pattern of missed contraindications at the intake stage, which is a meaningful positive signal. But no independent audit of Evernow's clinical protocols has been published.

What LegitScript Says

LegitScript, the verification body used by Google, payment processors, and pharmacies to assess online pharmacy and telehealth legitimacy, does not currently list Evernow as a certified telemedicine provider in its public database. This is not the same as a violation finding. Many legitimate telehealth companies have not pursued LegitScript certification. The absence is a gap in independent third-party verification, not evidence of wrongdoing.

State Medical Board Oversight

Telehealth prescribers must hold a license in the patient's state. Evernow operates in most U.S. States, though availability varies. If you receive a prescription through Evernow, the prescriber's name and license number should appear on the prescription label. You can verify that license through your state's medical board website. Women in states with stricter telemedicine prescribing rules (particularly around controlled substances, though MHT is not a controlled substance) may find limited provider availability.

Sex-Specific Physiology: Why Menopause Telehealth Is a Distinct Category

Menopausal hormone therapy is not a generic drug category. Its risks and benefits change across the female lifespan in ways that any prescribing platform must account for.

Perimenopause (Typically Mid-40s to Early 50s)

Perimenopause is characterized by erratic estrogen fluctuation rather than simple estrogen decline. Ovulation still occurs, meaning pregnancy remains possible until 12 consecutive months of amenorrhea are confirmed. This matters for any telehealth platform prescribing MHT: a perimenopausal woman who is not using contraception and has not reached confirmed menopause could theoretically be pregnant. FDA-approved MHT formulations are contraindicated in pregnancy (see Pregnancy and Lactation section below).

Evernow's intake process asks about last menstrual period and pregnancy status. Whether it systematically requires pregnancy testing before initiating MHT in perimenopausal women with recent cycles is not publicly documented in its clinical protocols.

Post-Menopause (12+ Months of Amenorrhea)

Post-menopause presents different risk considerations. The Women's Health Initiative study, which followed 16,608 women randomized to combined estrogen-progestin versus placebo, remains the largest randomized trial of MHT and continues to shape prescribing conservatism. Re-analysis of that data by age-at-initiation has since shown that women who start MHT within 10 years of menopause or before age 60 have a more favorable benefit-risk profile than older initiators. This "timing hypothesis" is central to current NAMS guidance and is the basis on which platforms like Evernow operate.

Hormonal Acne, PCOS, and Perimenopausal Crossover

Some women in their 40s present with both PCOS-related androgen excess and early perimenopause symptoms simultaneously. This overlap creates prescribing complexity that a standard menopause telehealth intake may not capture well. If you have a PCOS diagnosis, endometriosis, fibroids, or a history of hormone-sensitive cancer, a specialist visit before or alongside a telehealth menopause service is worth the extra step.

Pregnancy, Lactation, and Contraception: Required Safety Information

Menopausal hormone therapy is contraindicated in confirmed pregnancy. This applies to all systemic estrogen formulations, combined estrogen-progestin products, and micronized progesterone when used at MHT doses.

Pregnancy Risk During Perimenopause

Perimenopausal women often underestimate pregnancy risk. Ovulation is irregular but not absent. ACOG confirms that effective contraception is appropriate for perimenopausal women who do not want to conceive, and the organization recommends continuing contraception until menopause is confirmed (12 consecutive months without a period).

If you are using Evernow and have not yet reached confirmed menopause:

• Confirm you are not pregnant before starting MHT.
• Use reliable contraception if you do not want to conceive.
• Know that low-dose hormonal contraceptives can also manage perimenopausal symptoms and provide contraception simultaneously, though this is a separate clinical conversation from MHT.

Lactation

Systemic estrogen is generally avoided in breastfeeding women because estrogen may reduce milk supply. The FDA prescribing information for estradiol products advises caution in nursing mothers. Vaginal estrogen used at very low doses for GSM has minimal systemic absorption, but its safety in lactating women has not been specifically studied in large trials. Women who are postpartum and breastfeeding should not be using MHT for menopause symptoms, as they are not menopausal.

Non-Hormonal Options and Pregnancy Safety

Non-hormonal options Evernow may prescribe include SSRIs (paroxetine 7.5 mg, the only FDA-approved non-hormonal treatment for hot flashes, under the brand name Brisdelle), SNRIs, and gabapentin. Paroxetine carries FDA Pregnancy Category D, meaning evidence of fetal risk exists. Gabapentin is Pregnancy Category C. If you are perimenopausal and not using contraception reliably, discuss non-hormonal medication safety explicitly with your Evernow provider.

Who Evernow Is Right For and Who Should Look Elsewhere

A Good Fit

Evernow may work well for you if:

• You are in confirmed or late perimenopause with classic vasomotor symptoms (hot flashes, night sweats, sleep disruption)
• You have no significant cardiovascular history, VTE history, or active hormone-sensitive cancer
• You want FDA-approved MHT prescribed by a licensed clinician without a long in-person wait
• You are comfortable with asynchronous or low-synchrony communication for follow-up
• You have already had a recent well-woman exam and know your baseline labs

Situations That Call for More Specialized Care

Evernow may not be sufficient if:

• You are perimenopausal and still having cycles, and you need contraception alongside symptom management
• You have PCOS, endometriosis, fibroids, or a history of hormone-sensitive cancer
• You have undiagnosed or unexplained vaginal bleeding (a contraindication to empiric MHT)
• You have active liver disease or a personal history of VTE or stroke
• You need thyroid management, bone health monitoring, or integrated postpartum care
• Your symptoms are complex enough to require in-office examination or imaging

Women in postpartum or lactation periods are not candidates for MHT and should not be using this platform for hormone-related symptoms.

What the Evidence Gap Means for You

Women have been historically under-represented in many telehealth platform outcome studies, and Evernow has not published peer-reviewed outcome data on its patient population. The evidence base for MHT itself is strong, with decades of trial data and a 2022 meta-analysis in The Lancet covering over 100,000 women providing updated breast cancer risk estimates by formulation type. What is not established is whether Evernow's delivery model produces outcomes equivalent to, better than, or worse than in-person menopause care.

That gap is an honest answer, not a disqualifying one. The same gap exists for most telehealth platforms. The question worth asking is: does Evernow give you access to evidence-based MHT with licensed oversight that you would not otherwise get? For many women, the answer is yes.

"The data are clear that hormone therapy is the most effective treatment for menopausal vasomotor symptoms, and access barriers remain a serious problem," says Elena Vasquez, MD, WomanRx's reviewing ob-gyn. "Telehealth platforms that expand access to FDA-approved MHT serve a real need. The obligation is to make sure the intake and follow-up are rigorous enough to catch contraindications and adjust therapy when symptoms change."

How to Protect Yourself Before and During an Evernow Subscription

These steps reflect what the complaint record suggests goes wrong most often:

Before subscribing:

• Screenshot the current pricing page and membership terms before you pay.
• Confirm which states Evernow currently serves, and verify the prescriber's license in your state when you receive your first prescription.
• Ask explicitly whether your preferred pharmacy or the platform's pharmacy partner carries the specific formulation you are prescribed before paying.

During the subscription:

• Keep records of all clinician messages and response times.
• If your prescription is delayed beyond 72 hours without explanation, contact the pharmacy directly and then the platform's support team in writing (email, not chat, so you have a record).
• If you want to cancel, send a written cancellation request by email and request confirmation. Note the date.

If something goes wrong clinically:

• A prescribing error or safety concern should be reported to your state medical board and, if it involves a pharmacy, to your state pharmacy board.
• FDA MedWatch accepts reports of adverse events related to medications regardless of where they were prescribed.

Evernow Against the Competitive Field

The menopause telehealth space includes Midi Health, Alloy, Gennev, and others. Midi Health has pursued a synchronous-visit model with menopause-specialist clinicians. Alloy focuses on a streamlined questionnaire-to-prescription pathway similar to Evernow's. Gennev uses a hybrid model with both telehealth and in-person partnerships.

Each platform has its own complaint profile. Billing confusion and subscription cancellation issues appear across the category, not as an Evernow-specific failure. The differentiator to evaluate is clinical rigor: how thorough is the intake, how quickly do clinicians respond, and how does the platform handle a woman whose symptoms do not improve on initial therapy.

Evernow's specific differentiator has historically been price point and a questionnaire-first workflow. Its weakness, reflected in complaints, is customer-service responsiveness and subscription transparency.